Skip to main content
PLOS One logoLink to PLOS One
. 2022 Jun 24;17(6):e0270293. doi: 10.1371/journal.pone.0270293

Prevalence of depression and associated factors among adult cancer patients receiving chemotherapy during the era of COVID-19 in Ethiopia. Hospital-based cross-sectional study

Abebe Muche Belete 1,*, Anmut Alemagegn 2, Anemut Tilahun Mulu 3, Taklo Simeneh Yazie 4, Bekalu Bewket 5, Adisu Asefa 1, Wendimeneh Shibabaw Shiferaw 6
Editor: Muhammad Sajid Hamid Akash7
PMCID: PMC9232136  PMID: 35749489

Abstract

Background

Depression is a major public health problem among cancer patients undergoing chemotherapy. It compromises patient outcomes, resulting in higher rates of mortality. Currently, there are little data on the prevalence of depression in Sub-Sharan countries. Therefore, the current study was done to assess the prevalence of depression among adult cancer patients and its associated factors in Ethiopia.

Method

An institutional based cross-sectional study was conducted among 420 adult cancer patients from 1st March to April 30, 2021. Systematic random sampling technique was used to recruit participants. Depression was assessed using the Patient Health Questionnaire-9. The collected data were coded and entered into Epi-data version 4.2 and exported to SPSS version 25 for analysis. Bivariate binary logistic regression was performed to select factors that will be included in multivariate analysis, and variables with a p-value < 0.05 were included in multivariate analysis. In multivariate analysis, odds ratios and their 95% confidence intervals were computed and variables with p-value < 0.05 were considered to declare a significant association.

Results

In this study, the prevalence of depression was 33.1% (95% CI = 0.2858, 0.3761). Minimal symptoms of depression, minor depression, moderate depression, moderate severe depression, and severe depression were found to be 272 (64.8%), 9 (2.1%), 104 (24.8%), 28 (6.7%), and 7 (1.7%), respectively. Those cancer patients who had unemployed status, sacked from jobs, and had stage IV cancer were most likely to develop depression, whereas patients who completed primary education, colon, prostate and cervical cancer were less likely to have depression.

Conclusion

Depression is found to be a major public health concern for adult cancer patients in Ethiopia. To reduce the occurrence of depression among cancer patients, special attention is needed.

Background

Worldwide, new cancer cases, and cancer deaths were estimated to be 19.3 million and 10 million, respectively, in 2020. The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020 [1]. Well-recognized risk factors for cancer are tobacco use, poor physical activity, poor nutrition [2], obesity [3] and excessive alcohol consumption [4, 5]. The treatment of cancer includes three main modalities namely surgery, radiotherapy and chemotherapy. While the novel strategies may include targeted therapy, electric field treatments and vaccine therapy [6]. Chemotherapy is an intense and cyclic treatment with many side effects such as hair loss, nausea, vomiting and diarrhea [7]. Cyclic dependent kinase inhibitors that have emerged as a potent strategy for the treatment of advanced cancers [8]. The importance of chemotherapy for cure of cancer is increasing, especially with its use as adjuvants to local therapy. Besides, in advanced disease, chemotherapy has an expanding role in efforts to relieve cancer-related symptoms and to prolong life [9].

Cancer remains one of the most feared illnesses and the diagnosis of cancer has a huge psychological impact on the patients and their care-givers [10]. Many cancer patients suffer from psychological problems, such as depression. Cancer patients undergoing chemotherapy, usually experience various symptoms such as depression. Depression worsens during chemotherapy, persists for a long time after the end of chemotherapy, and it is also manifested in the recurrence of the disease [11]. This may interfere with the patient’s ability to cope with the burden of the illness, it may decrease the acceptance of treatment, extend hospitalization [12], reduce the quality of life [13, 14], and increase suicide risk [15]. Furthermore, the depression compromises patient outcomes, resulting in higher rates of mortality [1618], with estimates as high as a 26% greater mortality rate among patients with depressive symptoms and a 39% higher mortality rate among those with a diagnosis of major depression [19].

The epidemiology of depression among cancer patients was to 23.4% in China [20], 48.7% in Pakistan [21], 17% in Australia [22], 38.2% in Greece [23], 46.5% in Saudi Arabia [24], 67.7% in Rwandan [25], 25% in Addis Ababa-Ethiopia [26], and 58.4% in Gondar-Ethiopia [27]. Different studies showed several factors that are associated with depression such as cancer types [28], female sex [29], old age [14, 30], the duration of cancer [31] and type of treatment. Furthermore, a slightly higher incidence of depression was found among cancer patients who underwent chemotherapy than patients who had not received chemotherapy [32]. Besides, depressive symptoms were more prevalent across patients who were hospitalized compared with patients in the outpatient setting [33].

Regarding depression among cancer patients, most of the studies came from the developed world, and very limited studies addressed populations from low- and middle-income countries. Therefore, this study aimed to assess the prevalence of depression among cancer patients at Tikur Anbessa Specialized Hospital in Ethiopia.

Methods

Study area, design and period

The study was conducted at Tikur Anbessa Specialized Hospital (TASH) which is located in Addis Ababa, which is the capital city of Ethiopia. TASH oncology unit was established in 2015 under the Federal Minister of Health. It is located at Addis Ababa, Lideta Sub–City. The oncology unit provides health services for all cancer patients attending TASH from Addis Ababa city, and different regional states of Ethiopia. The oncology unit at TASH is the largest referral site in the country, providing service to more than 60,000 patients annually. It is the sole oncology referral and the only radiotherapy center in Ethiopia. The cross-sectional study design was employed from 1st March to April 30, 2021.

Source population

All adult cancer patients who had followed up at TASH and treated with chemotherapy have been taken as the source population.

Study population

All adult cancer patients under chemotherapy treatment and follow up service during the data collection period.

Eligibility criteria

Inclusion criteria

All adult cancer patients under chemotherapy and follow up at oncologic clinic in TASH during the data collection period.

Exclusion criteria

Patients who had communication or hearing impairments were excluded.

Sample size calculation and sampling techniques

The required sample size was determined using a single population proportion formula having the following assumptions: value for the 95% CI (Zα/2 = 1.96), the proportion of depression (P = 50%), and margin of error (d = 5%) Then, by adding 10% of study subjects as non-response rate, the final sample size was 422. The study subjects were selected using the systematic random sampling technique after determining the sampling fraction (k = 900/420 = 2) and the first participant was selected using the lottery method.

Study variables

Dependent variable

Depression (Yes/No).

Independent variables

Socio-demographic variables: Age, educational status, marital status, employment, and monthly income.

Psychosocial factors: Social and husband support, emotional violence, physical violence, and sexual violence.

Substance use: Use any substance like khat, alcohol, and cigarette.

Clinical characteristics: Stage of cancer, duration of the illness, comorbidity, type of cancer.

Family history of psychiatric illness: A family history (first-degree relatives) of psychiatric problems.

Data collection tools and procedures

A structured interviewer-administered questionnaire was used to collect data from all participants. Socio-demographic, clinical, and psychosocial factors were assessed using predefined checklists. The social support level was assessed using the Oslo social support scale-3. The Oslo social support-3 consists of three items assessing the level of social support. The sum score ranges from 3 to 14, with high values representing strong levels and low values representing poor levels of social support [34]. Depression was assessed using Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 comprises nine items that can be scored from 0 (not at all) to 3 (nearly every day) and the total score ranges from 0 to 27 to measure depression severity [35, 36]. The standard PHQ9 cut off points 1–4, 5–9, 10–14, 15–19 and greater than or equal to20 was considered as having minimal depression symptoms, minor depression, moderate depression, moderately severe and major depression (severe), respectively. Then, the total depression score was dichotomized, and those cancer patients who scored 10 and above were considered as having symptomatic depression. PHQ-9 is a validated tool in Ethiopia [37].

Data analysis

The collected data were entered into Epi-data version 4.2 and analyzed by SPSS version 25. Bivariate logistic regression was done and, variables with p-value < 0.05 were entered in to a multivariate logistic model. In multivariate logistic regression analysis, adjusted odds ratio with a p-value of < 0.05 was considered statistically significant.

Data quality control

The questionnaire was prepared in English and translated to Amharic and translated back to English before the data collection process. The data collection instrument was pre-tested on 5% of the sample to improve the language clarity and appropriateness of the data collection tools. The estimated time required, and necessary amendments were made after the piloting of the questionnaire. The data were collected by four BSc nursing professionals who were trained for one day on the techniques of data collection, purpose of the study, and ethical considerations. The researcher checked the accuracy, completeness and consistency of questionnaires completed by the data collectors to ensure the quality of data and visited the data collectors as many times as possible to check whether he/she collected the data appropriately. The Amharic version of PHQ-9 is validated in Ethiopia.

Ethical approval and consent to participate

Ethical clearance was obtained from Addis Ababa University, College of Health Sciences, School of Nursing and Midwifery, Research and Ethics Review Committee (IRB protocol: AAU/CHS/NSG/0020). A collaboration letter for data collection was also obtained from TASH. Verbal informed consent was obtained from each participant. The objective of the study and methods of data collection were briefly clarified and explained for each participant, before enrolling any eligible study participants. Then, verbal informed consent was obtained from each participant. As the study does not impose any harm to the participants and from the experience, patients feel their confidentiality is secured more when they give verbal informed consent than written informed consent. To assure confidentiality, a code number was used instead of the participants’ name or identification number.

Operational definitions

Poor social support: cancer patients who scored 3–8 on the (Oslo-3) social support scale during cancer.

Moderate social support: cancer patients who scored 9–11 on the (Oslo-3) social support scale during cancer.

Strong social support: cancer patients who scored 12–14 on the (Oslo-3) social support scale during cancer.

Result

Socio-demographic characteristics of the participants

Four hundred twenty participants were included in the final analysis in this study with a non-response rate of 99.5%. Majority, 243 (57.9%) were female, 220 (52.4%) were in the age between 35 and 51 years and 103 (24.5%) were above the age of 52 years old. The mean and standard deviation age of the participants was 43.6 (SD±12.37) years, over 297 (69%) were married, and 119 (28.3%) completed secondary school education (Table 1).

Table 1. Socio-demographic characteristics of study participants among adult cancer patients at the oncology clinic of TASH, Addis Ababa, Ethiopia, 2021.

Variables Category Frequency Percent
Sex Female 243 57.9
Male 177 42.1
Age in years 18–34 97 23.1
35–51 220 52.4
≥52 103 24.5
Educational status Illiterate 45 10.7
Read and write only 77 18.3
Primary 94 22.4
Secondary 119 28.3
College/university 85 20.2
Marital status Single 47 11.2
Married 290 69
Divorced 16 3.8
Widowed/r 67 16
Occupation Private work 106 25.2
Civil servant 90 21.4
House wife 116 27.6
Others 108 25.7
Income Low 60 14.3
Medium 113 26.9
High 247 58.8

Clinical and behavioral characteristics of the study participants

The clinical characteristics of the study participants indicate that; 142 (33.8%) have breast cancer, 120 (28.6%) were on stage 2 cancer, 52 (12.4%) drunk alcohol but now quitted and 33 (7.9%) of participants quitted smoke. Of the total study participants, 6 (1.4%) study participants had a family history of known mental illness and 2(0.5%) had a diagnosis of chronic kidney disease (Table 2).

Table 2. Clinical and behavioral characteristics of study participants among adult cancer patients at oncology clinic of TASH, Addis Ababa, Ethiopia, 2021.

Variables Category Frequency Percent
Stage of cancer Stage 1 28 6.7
Stage 2 99 23.6
Stage 3 120 28.6
Stage 4 173 41.6
Type of cancer Breast cancer 156 37.1
Colon cancer 53 12.6
Prostate cancer 32 7.6
NPC 35 8.3
Cervical cancer 52 12.4
Lung cancer 33 7.9
Bladder cancer 12 2.9
Thyroid cancer 6 1.4
Hematologic cancer 12 2.9
Edwing cancer 24 5.7
Other 5 1.2
Months since diagnosis <6 203 48.3
7–12 113 26.9
>12 104 24.8
Duration since start of chemotherapy 1–3 months 190 45.2
4–6 months 110 26.2
>6 months 120 28.6
Family history with known mental illness Yes 6 1.4
No 414 98.6
Hypertension Yes 1 0.2
No 419 99.8
Diabetes Mellitus Yes 1 0.2
No 419 99.8
Chronic kidney disease Yes 2 0.5
No 418 99.5
Cardiovascular disease Yes 1 0.2
No 419 99.8
Presence of comorbidities Yes 17 4
No 403 96
Chewing Currently chat chewing 1 0.2
Previously drunker 29 6.9
Never used 390 92.9
Alcohol Currently drinker 3 0.7
Previously drunker 52 12.4
Never drank 365 86.9
Smoking status Currently smoker 1 0.2
Previously smoker 33 7.9
Never smoke 386 91.9

Note: presence of comorbidities = include hypertension, diabetes mellitus and kidney disease

Abbreviations: SD = standard deviation, chronic illness =, NPC = Naso pharengyal, other type of cancer include = Kaposi sarcoma, adenocarcinoma, and oropharia cancer

Psychosocial factors (in the last 6 months) of cancer patients

From the total of participants, 53 (12.6%) responded that their family or close relatives had died and 30 (7.1%) participants responded as having died a spouse, parent, or child during the disease. 125 (29.8%) responded to having major financial crisis. 20(4.8%) responded to being sacked from their job (Table 3).

Table 3. Psychosocial factors (in the last 6 months) of adult cancer patients receiving chemotherapy at TASH, Addis Ababa, Ethiopia, 2021.

Variable Category Frequency Percent
Serious illness or injury during cancer Yes 7 1.7
No 413 98.3
Close relative serious illness or injury or assault Yes 9 2.1
No 411 97.9
Died spouse, parent or child Yes 30 7.1
No 390 92.9
Died family or close relatives Yes 53 12.6
No 367 87.4
Yes 125 29.8
Major financial crisis
No 295 70.2
Sacked from job Yes 20 4.8
No 400 95.2
Unemployed/not able to work Yes 41 9.8
No 379 90.2
Separation due to marital difficulty Yes 11 2.6
No 409 97.4
Broken off a steady relationship Yes 11 2.6
No 409 97.4
Serious problems with close friend, neighbor /relative Yes 19 4.5
No 401 95.5
Lost/stolen property which mattered a lot Yes 20 4.8
No 400 95.2
Any problems with police/court Yes 11 2.6
No 409 97.4
Trauma by your wife or husband Yes 6 1.4
No 414 98.6
Forced sexual activity Yes 1 0.2
No 419 99.8

Social support among cancer patients

Of the total participants, 94 (22.4%), 207 (49.3%) and 119 (28.3%) had poor, moderate and strong social support, respectively (Fig 1).

Fig 1. Social support of adult cancer patients.

Fig 1

Prevalence of depression among cancer patients

The overall prevalence of depression among adult cancer patients was 33.1% (95% CI = 0.2858, 0.3761) (Fig 2).

Fig 2. Prevalence of depression among adult cancer patients.

Fig 2

Minimal symptoms of depression, minor depression, moderate depression, moderate severe depression, and severe depression were found to be 272 (64.8%), 9 (2.1%), 104 (24.8%), 28 (6.7%), and 7 (1.7%), respectively. A higher prevalence of depression was seen among patients with nasopharyngeal cancer (NPC) 51%, followed by thyroid cancer 50%, and breast cancer 42% (Fig 3).

Fig 3. Depression among each type of cancer.

Fig 3

Factors associated to depression

In bivariate logistic regression analysis, education, income, type of cancer, the stage of cancer, serious illness or assault happened to close relatives, major financial problem, unemployed, sacked from a job, a serious problem with a close friend or neighborhood, having some problems with the police or courts, and social support were significantly associated with depression (p <0.05). When these variables were entered and analyzed in multivariate logistic regression, education, colon cancer, prostate cancer, cervical cancer, stage of cancer, unemployed and sacked from job were significantly associated with depression.

The results showed that participants who completed their primary education were less likely to develop depression than those who had no formal education (AOR: 0.414, 95% CI = 0.206–0.829). Additionally, patients with colon cancer were less likely to develop depression as compared to breast cancer (AOR: 0.364, 95% CI = 0.156–0.847). Besides, patients with prostate cancer and cervical cancer were less likely to develop depression compared to patients with breast cancer (AOR: 0.184, 95% CI = 0.064–0.525; AOR: 0.334, 95% CI = 0.148–0.752, respectively). Patients with Stage four cancer were seven times more likely to develop depression compared to patients with stage one (AOR: 7.444, 95% CI = 1.943–28.523). Being unemployed was two times more likely risk of developing depression compared to being employed (AOR: 2.263, 95% CI = 1.043–4.913), and patients sacked from job were three times more likely to develop depression compared to no sacke from job (AOR: 3.404, 95% CI = 1.049–11.042) (Table 4).

Table 4. Bivariate and multivariate logistic regression analysis of independent factors to depression among cancer patients at the oncology clinic of TASH, Addis Ababa, Ethiopia, 2021.

Variables Category Depression COR(95%CI) AOR(95%CI)
No (n, %) Yes (n, %)
Education No formal education 70(57.4) 52(42.) 1 1
Primary 71(75.5) 23(24.5) 0.436(0.241–0.788)* 0.414(0.206,0.829)*
Secondary 83(69.7) 36(30.3) 0.584(0.343–0.993)* 0.538(0.279,1.037)
Higher 57(67.1) 28(32.9) 0.661(0.371–1.178) 0.621(0.291,1.325)
Income Low 32(53.3) 28(46.7) 1.827(1.03,3.239)* 1.211(0.573,2.56)
Medium 82(72.6) 31(27.4) 0.789(0.483–1.29) 0.791(0.425,1.473)
High 167(67.6) 80(32.4) 1 1
Type of cancer Breast cancer 90(57.7) 66(42.3) 1 1
Colon cancer 39(73.6) 14(26.4) 0.49(0.246,0.974)* 0.364(0.156,0.847)*
Prostate cancer 26(81.3) 6(18.8) 0.315(0.123,0.808)* 0.184(0.064,0.525)*
NPC 17(48.6) 18(51.4) 1.444(0.692,3.011) 1.408(0.609,3.256)
Cervical cancer 41(78.8) 11(21.2) 0.366(0.175,0.765)* 0.334(0.148,0.752)*
Lung cancer 25(75.8) 8(24.2) 0.436(0.185,1.028) 0.407(0.154,1.076)
Bladder cancer 8(66.7) 4(33.3) 0.682(0.197,2.36) 0.775(0.196,3.065)
Thyroid cancer 3(50) 3(50) 1.364(0.267,6.97) 1.291(0.19,8.791)
Hematologic 10(83.3) 2(16.7) 0.273(0.058,1.286) 0.559(0.098,3.184)
Edwing cancer 17(70.8) 7(29.2) 0.561(0.22,1.431) 0.617(0.215,1.766)
Other 5(100) - -
Stage of cancer Stage 1 25(89.3) 3(10.7) 1 1
Stage 2 81(81.8) 18(19.2) 1.852(0.504,6.808) 1.893(0.461,7.764)
Stage 3 85(70.8) 35(29.2) 3.431(0.973,12.104) 3.558(0.904,14.009)
Stage 4 90(52) 83(48) 7.685(2.237,26.402)* 7.444(1.943,28.523)*
Serious illness, injury or assault happened to a close relatives Yes 35(51.5) 33(48.5) 2.188(1.291,3.707)* 1.9(0.958,3.771)
No 246(69.9) 106(30.1) 1 1
A major financial crisis Yes 80(56.7) 61(43.3) 0.509(0.333,0.777)* 1.597(0.965,2.642)
No 201(72) 78(28) 1 1
Unemployed Yes 16(39) 25(61) 3.632(1.868,7061)* 2.263(1.043,4.913)*
No 165(69.9) 114(30.1) 1 1
Sacked from job Yes 5(27.8) 13(72.2) 5.695(1.988,16.319)* 3.404(1.049,11.042)*
No 276(68.7) 126(31.3) 1 1
A serious problem with a close friend, neighborhood Yes 7(36.8) 12(63.2) 3.699(1.422, 9.617)* 3.177(0.872,11.571)
No 274(68.3) 127(31.7) 1 1
Have you had any problems with the police or courts Yes 4(36.4) 7(63.6) 3.672(1.057,12.765)* 0.924(0.164,5.199)
No 277(67.7) 132(32.3) 1 1
Social support Poor 91(56.9) 69(43.1) 1.896(1.106,3.248)* 1.641(0.851,3.165)
Moderate 120(74.1) 42(25.9) 0.875(0.499,1.535) 1.196(0.622,2.3)
Strong 70(71.4) 28(28.6) 1 1

NPC: Naso Pharyngeal Cancer; N: number; COR = Crud Odds ratio; AOR = Adjusted Odds Ratio; CI = Confidence Interval; %: percent

* = statistically significant by univariate logistic regression

** = statistically significant by multivariate logistic regression

Discussion

The overall prevalence of depression among adult cancer patients was 33.1% in this study. This finding was higher than the results of a studies conducted in Jordan-23.4% [38], India-22% [39], Iran-21.3% [31], Asia-29.6% [40], German-24% [41] and Ethiopia-Addis Ababa-25.0% [26]. However, it was lower than the findings of a study conducted in China- 66.7% [42], Ethiopia-Gondar-70.86% [43], Greece-38.2% [23], German 36.9% [44], Ethiopia 36.9% [45], and Rwanda 67.7% [46]. The variation might be due to differences in instruments to assess depression, criteria to define depression, and included cancer populations with respect to cancer type, stage and treatment modality.

Available data also suggest that cancer may increase patients’ susceptibility to depression in several ways. To mention some, a reaction to a severe diagnosis and the forthcoming deterioration of health status may constitute a risk factor for depression; treatment with immune response modifiers and chemotherapy regimens, and experiencing of metabolic and endocrine alterations, chronic pain and extensive surgical interventions, may represent additional contributing factors [47, 48].

Patients who are at a high risk of depression require special attention and a strong support system. psychological problems hinder their ability to cope with treatment and symptoms, as well as recovery from chemotherapy side effects and cancer impact [49]. Depression in patients with cancer can be prevented and prophylactic treatment should be administered during oncological treatment [50]. The treatment of depression must be started at an early stage. It can take a long time to make patients aware of the psychological nature of their difficulties, having this consideration, encourage them to request a psychological consultation or to accept the prescription of psychotropic or, in particular, antidepressant medicaments [51].

The current study found several associated factors for depression among cancer patients in Ethiopia. Those associated factors were primary education, unemployment, sacked from jobs, colon cancer, prostate cancer, cervical cancer and cancer stage. Study participants who completed their primary education were less likely to develop depression than who had no formal education. This finding was in a line with the findings of studies conducted in Ethiopia [21, 26, 43]. Education may offer opportunities for developing interventions to reduce the disease burden of depression. Low education levels are linked with depression and that higher levels of education play a preventive role against depression [21]. Being unemployed was found to have 2.2 times a more likely risk to develop depression compared to being employed, which is supported by other studies [43, 52]. Patients sacked from job were 3.4 times more likely to develop depression compared to no sack from job. Having no or low education level, unemployed status, and being sacked from jobs, negatively influence depression symptoms. These often make the adaption process of psychological disorders to be longer and harder [53]. The experience of being diagnosed with cancer could become a source of distress in addition to the disruption in the work role. Failure to remain in employment could deprive an individual from social contact and well-being.

Patients who had colon, prostate and cervical cancer were less likely to have depression compared with those with breast cancer. This finding was similar in other studies [54]. The possible explanation for this occurrence might be increased worriedness of patients after breast cancer diagnosis, to shortened survival time, recurrence and metastasis. Furthermore, female patients face impaired body image and decreased quality of sexual life caused by surgery and other treatments. Therefore, compared with other malignant tumors, the incidence of depression and other psychiatric symptoms in breast cancer patients are higher, which is also closely related to the lack of female secondary characteristics and physical symptoms such as nausea, vomiting, fatigue, hair loss, and insomnia caused by chemotherapy [55].

Moreover, patients with stage four had 7.4 times more likely at risk of developing depression compared to patients with stage one. Similar findings have been found in other studies [14, 46]. This might be due to when the stage is advanced, patients may fear or stress. Studies found that individuals diagnosed at an advanced stage have a higher risk of developing depression compared with those diagnosed at an early stage [14, 56]. Patients with advanced-stage cancer generally have a greater need for supportive care, due to poor physical functioning, a greater symptom burden, and higher levels of distress, and depression than other cancer patients [57]. Earlier and more intensive supportive care for patients with cancer reduces symptom burden and may prolong life for patients with advanced disease [58]. For managing their distress, pharmacotherapy and psychotherapy are effective for managing depression among advanced cancer patients [59].

The preventive strategies toward the risk factors of depression include education and counselling programs that must be designed and planned according to the patient’s wishes and learning needs [60]. The current study is conducted in light with some limitations. First, some of the depression symptoms may have been due to the cancer itself or its treatment rather than due to depression.

Conclusion

Depression is found to be a major public health problem for adult cancer patients in Ethiopia. Those cancer patients who had unemployed status, sacked from jobs, and stage IV cancer were most likely to develop depression, whereas patients having completed primary education, colon, prostate and cervical cancer were less likely to have depression. To reduce the prevalence of depression among cancer patients, designing strategies and special attention are needed to bring changes in the psychological status of patients in advanced disease stage.

Supporting information

S1 Text. Sociodemographic questions.

(DOCX)

S2 Text. Clinical and behavioral characteristics of questions.

(DOCX)

S1 Table. Psychosocial questions.

(DOCX)

S2 Table. Socila support questions.

(DOCX)

S3 Table. Tools used to assess depression.

(DOCX)

S1 File. Data collection tool.

(DOCX)

Acknowledgments

First of all, we want to give appreciation to Addis Ababa University, College of Health Science post graduate office for giving us this chance to participate in the research activity. We would like to thank the patients, data collectors, and supervisors who were involved in this study and spent their valuable time responding to our study.

Abbreviation

AOR

Adjusted Odds Ratio

CI

Confidence Interval

COR

Crud Odds ratio

PHQ

Patient Health Questionnaire

SD

Standard Deviation

SPSS

Statistical Package for Social Sciences

TASH

Tikur Anbessa Specialized Hospital

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209–49. [DOI] [PubMed] [Google Scholar]
  • 2.White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Jane Henley S. Age and Cancer Risk: A Potentially Modifiable Relationship. American Journal of Preventive Medicine. 2014;46(3). doi: 10.1016/j.amepre.2013.10.029 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism. 2019;92:121–35. doi: 10.1016/j.metabol.2018.11.001 [DOI] [PubMed] [Google Scholar]
  • 4.Key TJ, Allen NE, Spencer EA, Travis RC. The effect of diet on risk of cancer. The Lancet. 2002;360(9336):861–8. doi: 10.1016/S0140-6736(02)09958-0 [DOI] [PubMed] [Google Scholar]
  • 5.Seitz HK, Becker P. Alcohol metabolism and cancer risk. Alcohol Res Health. 2007;30(1):38–47. [PMC free article] [PubMed] [Google Scholar]
  • 6.Rasheed S, Rehman K, Akash MSH. An insight into the risk factors of brain tumors and their therapeutic interventions. Biomedicine & Pharmacotherapy. 2021;143. doi: 10.1016/j.biopha.2021.112119 [DOI] [PubMed] [Google Scholar]
  • 7.Pandey M, Sarita GP, Devi N, Thomas BC, Hussain BM, Krishnan R. Distress, anxiety, and depression in cancer patients undergoing chemotherapy. World Journal of Surgical Oncology. 2006;4(1):68. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Chohan TA, Qayyum A, Rehman K, Tariq M, Akash MSH. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers. Biomedicine & Pharmacotherapy. 2018;107:1326–41. doi: 10.1016/j.biopha.2018.08.116 [DOI] [PubMed] [Google Scholar]
  • 9.Nygren P. What is cancer chemotherapy? Acta Oncologica. 2001;40(2–3):166–74. doi: 10.1080/02841860151116204 [DOI] [PubMed] [Google Scholar]
  • 10.Ng CG, Boks MPM, Zainal NZ, de Wit NJ. The prevalence and pharmacotherapy of depression in cancer patients. Journal of Affective Disorders. 2011;131(1):1–7. doi: 10.1016/j.jad.2010.07.034 [DOI] [PubMed] [Google Scholar]
  • 11.Polikandrioti M, Evaggelou E, Zerva S, Zerdila M, Koukoularis D, Kyritsi E. Evaluation of depression in patients undergoing chemotherapy. Health Science Journal. 2008;2(3). [Google Scholar]
  • 12.Prieto JM, Blanch J, Atala J, Carreras E, Rovira M, Cirera E, et al. Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. Journal of Clinical Oncology. 2002;20(7):1907–17. doi: 10.1200/JCO.2002.07.101 [DOI] [PubMed] [Google Scholar]
  • 13.So WK, Marsh G, Ling WM, Leung FY, Lo JC, Yeung M, et al. Anxiety, depression and quality of life among Chinese breast cancer patients during adjuvant therapy. European journal of oncology nursing: the official journal of European Oncology Nursing Society. 2010;14(1):17–22. doi: 10.1016/j.ejon.2009.07.005 [DOI] [PubMed] [Google Scholar]
  • 14.Weiss Wiesel TR, Nelson CJ, Tew WP, Hardt M, Mohile SG, Owusu C, et al. The relationship between age, anxiety, and depression in older adults with cancer. Psycho‐Oncology. 2015;24(6):712–7. doi: 10.1002/pon.3638 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Krebber A, Buffart L, Kleijn G, Riepma I, De Bree R, Leemans C, et al. Prevalence of depression in cancer patients: a meta‐analysis of diagnostic interviews and self‐report instruments. Psycho‐Oncology. 2014;23(2):121–30. doi: 10.1002/pon.3409 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychol Med. 2010;40(11):1797–810. doi: 10.1017/S0033291709992285 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Satin JR. Review: depression is associated with increased cancer mortality. Evidence-based mental health. 2010;13(2):41. doi: 10.1136/ebmh.13.2.41 [DOI] [PubMed] [Google Scholar]
  • 18.Smith HR. Depression in cancer patients: Pathogenesis, implications and treatment. Oncology letters. 2015;9(4):1509–14. doi: 10.3892/ol.2015.2944 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a meta‐analysis. Cancer. 2009;115(22):5349–61. doi: 10.1002/cncr.24561 [DOI] [PubMed] [Google Scholar]
  • 20.Wang Y, Duan Z, Ma Z, Mao Y, Li X, Wilson A, et al. Epidemiology of mental health problems among patients with cancer during COVID-19 pandemic. Translational Psychiatry. 2020. 10(263). doi: 10.1038/s41398-020-00950-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Khalil A, Faheem M, Fahim A, Innocent H, Mansoor Z, Rizvi S, et al. Prevalence of Depression and Anxiety amongst Cancer Patients in a Hospital Setting: A Cross-Sectional Study. Psychiatry Journal. 2016;2016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Clinton-McHarg T, Carey M, Sanson-Fisher R, Tzelepis F, Bryant J, Williamson A. Anxiety and depression among haematological cancer patients attending treatment centres: Prevalence and predictors. Journal of Affective Disorders 2014;165:176–81. doi: 10.1016/j.jad.2014.04.072 [DOI] [PubMed] [Google Scholar]
  • 23.Tsaras K, Papathanasiou IV, Mitsi D, Veneti A, Kelesi M, Zyga S, et al. Assessment of Depression and Anxiety in Breast Cancer Patients: Prevalence and Associated Factors. Asian Pac J Cancer Prev. 2018;19(6):1661–9. doi: 10.22034/APJCP.2018.19.6.1661 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Abuelgasim KA, Ahmed GY, Alqahtani JA, Alayed AM, Alaskar AS, Malik MA. Depression and anxiety in patients with hematological malignancies, prevalence, and associated factors. Saudi Med J 2016;37(8):877–81. doi: 10.15537/smj.2016.8.14597 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Uwayezu MG, Gishoma D, Sego R, Mukeshimana M, Collins A. Anxiety and Depression Among Cancer Patients: Prevalence and Associated Factors at a Rwandan Referral Hospital. Rwanda Journal of Medicine and Health Sciences 2019;2(2). [Google Scholar]
  • 26.Wondimagegnehu A, Abebe W, Abraha A, Teferra S. Depression and social support among breast cancer patients in Addis Ababa, Ethiopia. BMC cancer. 2019;19(1):836. doi: 10.1186/s12885-019-6007-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Berihun F, Haile S, Abawa M, Mulatie M, Shimeka A. Prevalence and correlates of anxiety and depression among cancer patients in the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia. Arch Depress Anxiety 2017;3(2):042–8. [Google Scholar]
  • 28.Vodermaier A, Linden W, MacKenzie R, Greig D, Marshall C. Disease stage predicts post-diagnosis anxiety and depression only in some types of cancer. British Journal of Cancer. 2011;105(12):1814–7. doi: 10.1038/bjc.2011.503 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Linden W, Vodermaier A, MacKenzie R, Greig D. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. Journal of affective disorders. 2012;141(2–3):343–51. doi: 10.1016/j.jad.2012.03.025 [DOI] [PubMed] [Google Scholar]
  • 30.Nelson CJ, Weinberger MI, Balk E, Holland J, Breitbart W, Roth AJ. The chronology of distress, anxiety, and depression in older prostate cancer patients. The oncologist. 2009;14(9):891–9. doi: 10.1634/theoncologist.2009-0059 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Nikbakhsh N, Moudi S, Abbasian S, Khafri S. Prevalence of depression and anxiety among cancer patients. Caspian J Intern Med. 2014;5(3):167–70. [PMC free article] [PubMed] [Google Scholar]
  • 32.Bhattacharyya S, Bhattacherjee S, Mandal T, Das DK. Depression in cancer patients undergoing chemotherapy in a tertiary care hospital of North Bengal, India. Indian Journal of Public Health. 2017;61(1):14. doi: 10.4103/0019-557X.200252 [DOI] [PubMed] [Google Scholar]
  • 33.Naser AY, Hameed AN, Mustafa N, Alwafi H, Dahmash EZ, Alyami HS, et al. Depression and Anxiety in Patients With Cancer: A Cross-Sectional Study. Frontiers in Psychology. 2021;12(1067). doi: 10.3389/fpsyg.2021.585534 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Kocalevent R-D, Berg L, Beutel ME, Hinz A, Zenger M, Härter M, et al. Social support in the general population: standardization of the Oslo social support scale (OSSS-3). BMC psychology. 2018;6(1):1–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Kroenke K, Spitzer RL, Williams JB. The PHQ‐9: validity of a brief depression severity measure. Journal of general internal medicine. 2001;16(9):606–13. doi: 10.1046/j.1525-1497.2001.016009606.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Löwe B, Kroenke K, Herzog W, Gräfe K. Measuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9). Journal of affective disorders. 2004;81(1):61–6. doi: 10.1016/S0165-0327(03)00198-8 [DOI] [PubMed] [Google Scholar]
  • 37.Degefa M, Dubale B, Bayouh F, Ayele B, Zewde Y. Validation of the PHQ-9 depression scale in Ethiopian cancer patients attending the oncology clinic at Tikur Anbessa specialized hospital. BMC Psychiatry. 2020;20(1):446. doi: 10.1186/s12888-020-02850-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Naser AY, Hameed AN, Mustafa N, Alwafi H, Dahmash EZ, Alyami HS, et al. Depression and anxiety in patients with cancer. A cross sectiponal study. Front Psychol. 2021;12(585534). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Purkayastha D, Venkateswaran C, Nayar K, Unnikrishnan U. Prevalence of depression in breast cancer patients and its association with their quality of life: A cross-sectional observational study. Indian journal of palliative care. 2017;23(3):268. doi: 10.4103/IJPC.IJPC_6_17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Maneeton B, Maneeton N, Mahathep P. Prevalence of depression and its correlations: a cross-sectional study in Thai cancer patients. Asian Pacific Journal of Cancer Prevention. 2012;13(5):2039–43. doi: 10.7314/apjcp.2012.13.5.2039 [DOI] [PubMed] [Google Scholar]
  • 41.Hartung T, Brähler E, Faller H, Härter M, Hinz A, Johansen C, et al. The risk of being depressed is significantly higher in cancer patients than in the general population: prevalence and severity of depressive symptoms across major cancer types. European Journal of Cancer. 2017;72:46–53. doi: 10.1016/j.ejca.2016.11.017 [DOI] [PubMed] [Google Scholar]
  • 42.Hong JS, Tian J. Prevalence of anxiety and depression and their risk factors in Chinese cancer patients. Supportive Care in Cancer. 2014;22(2):453–9. doi: 10.1007/s00520-013-1997-y [DOI] [PubMed] [Google Scholar]
  • 43.Baraki AG, Tessema GM, Demeke EA. High burden of depression among cancer patients on chemotherapy in University of Gondar comprehensive hospital and Felege Hiwot referral hospital, Northwest Ethiopia. Plos one. 2020;15(8). doi: 10.1371/journal.pone.0237837 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Jacob L, Bleicher L, Kostev K, Kalder M. Prevalence of depression, anxiety and their risk factors in German women with breast cancer in general and gynecological practices. Journal of Cancer Research and Clinical Oncology. 2016;142(2):447–52. doi: 10.1007/s00432-015-2048-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Alemayehu M, Deyessa N, Medihin G, Fekadu A. A descriptive analysis of depression and pain complaints among patients with cancer in a low income country. PloS one. 2018;13(3). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Uwayezu MG, Gishoma D, Sego R, Mukeshimana M, Collins A. Anxiety and depression among cancer patients: prevalence and associated factors at a Rwandan referral hospital. Rwanda Journal of Medicine and Health Sciences. 2019;2(2):118–25. [Google Scholar]
  • 47.Irwin MR. Depression and insomnia in cancer: prevalence, risk factors, and effects on cancer outcomes. Current psychiatry reports. 2013;15(11):1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Sotelo JL, Musselman D, Nemeroff C. The biology of depression in cancer and the relationship between depression and cancer progression. International Review of Psychiatry. 2014;26(1):16–30. doi: 10.3109/09540261.2013.875891 [DOI] [PubMed] [Google Scholar]
  • 49.Kim YH, Choi KS, Han K, Kim HW. A psychological intervention programme for patients with breast cancer under chemotherapy and at a high risk of depression: A randomised clinical trial. Journal of Clinical Nursing. 2018;27(3–4):572–81. doi: 10.1111/jocn.13910 [DOI] [PubMed] [Google Scholar]
  • 50.Zahid JA, Grummedal O, Madsen MT, Gögenur I. Prevention of depression in patients with cancer: A systematic review and meta-analysis of randomized controlled trials. Journal of Psychiatric Research. 2020;120:113–23. doi: 10.1016/j.jpsychires.2019.10.009 [DOI] [PubMed] [Google Scholar]
  • 51.Dauchy S, Dolbeault S, Reich M. Depression in cancer patients. EJC Supplements. 2013;11(2):205. doi: 10.1016/j.ejcsup.2013.07.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Friberg AS, Rask Moustsen I, Benzon Larsen S, Hartung T, Wreford Andersen E, Halgren Olsen M, et al. Educational level and the risk of depression after prostate cancer. Acta Oncologica. 2019;58(5):722–9. doi: 10.1080/0284186X.2019.1566773 [DOI] [PubMed] [Google Scholar]
  • 53.Li Z, Geng W, Yin J, Zhang J. Effect of one comprehensive education course to lower anxiety and depression among Chinese breast cancer patients during the postoperative radiotherapy period—one randomized clinical trial. Radiation Oncology. 2018;13(1):111. doi: 10.1186/s13014-018-1054-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Alwhaibi M, Sambamoorthi U, Madhavan S, Bias T, Kelly K, Walkup J. Cancer Type and Risk of Newly Diagnosed Depression Among Elderly Medicare Beneficiaries With Incident Breast, Colorectal, and Prostate Cancers. J Natl Compr Canc Netw. 2017;15(1):46–55. doi: 10.6004/jnccn.2017.0006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Zhu G, Li J, Li J, Wang X, Dai M, Chen J. Depression and survival of breast cancer patients: A protocol for systematic review and meta-analysis. Medicine. 2020;99(48). doi: 10.1097/MD.0000000000023399 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Danese M, O’malley C, Lindquist K, Gleeson M, Griffiths R. An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer. Annals of Oncology. 2012;23(7):1756–65. doi: 10.1093/annonc/mdr486 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Quist M, Adamsen L, Rørth M, Laursen JH, Christensen KB, Langer SW. The impact of a multidimensional exercise intervention on physical and functional capacity, anxiety, and depression in patients with advanced-stage lung cancer undergoing chemotherapy. Integrative cancer therapies. 2015;14(4):341–9. doi: 10.1177/1534735415572887 [DOI] [PubMed] [Google Scholar]
  • 58.Rosenstein DL. Depression and end-of-life care for patients with cancer. Dialogues in clinical neuroscience. 2022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Akechi T. Psychotherapy for Depression Among Patients with Advanced Cancer. Japanese Journal of Clinical Oncology. 2012;42(12):1113–9. doi: 10.1093/jjco/hys152 [DOI] [PubMed] [Google Scholar]
  • 60.Djurdjević A, Nikolić S. Education of cancer patients—a psychosocial support in the holistic anticancer treatment. J BUON. 2006;11(2):217–21. [PubMed] [Google Scholar]

Decision Letter 0

Muhammad Sajid Hamid Akash

4 Apr 2022

PONE-D-22-06018Prevalence of depression and associated factors among adult cancer patients receiving chemotherapy during the era of COVID-19 in Ethiopia. A Hospital based cross sectional studyPLOS ONE

Dear Dr. Belete,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

I have received the reports from our advisors on your manuscript which you submitted to PLOS ONE.

Based on the comments received, I feel that your manuscript could be reconsidered for publication should you be prepared to incorporate major revisions.

When preparing your revised manuscript, you are asked to carefully consider the reviewer comments below and submit a list of responses to the comments.

Editor Comments: The paper should be checked by a professional speaker of English before complete acceptance.

Please submit your revised manuscript by May 19 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Muhammad Sajid Hamid Akash

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf  2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.  Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free. Upon resubmission, please provide the following: The name of the colleague or the details of the professional service that edited your manuscript A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file) A clean copy of the edited manuscript (uploaded as the new *manuscript* file)” 3. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information. If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information. 4. Thank you for stating the following financial disclosure:  "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." At this time, please address the following queries: a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution. b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”c) If any authors received a salary from any of your funders, please state which authors and which funders.d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.” Please include your amended statements within your cover letter; we will change the online submission form on your behalf. 5. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The author presented an original article on ‘Prevalence of depression and associated factors among adult cancer patients receiving chemotherapy during the era of COVID-19 in Ethiopia. A Hospital based cross sectional study’. The manuscript needs to be improved regarding the following aspects.

• Cancer chemotherapy should be described in detail to strengthen your research study moreover, overall associated factors for cancer risk should also be included in the introduction part, Biomed Pharmacother. 2021; 143: 112119. https://doi.org/10.1016/j.biopha.2021.112119

• In the discussion section, discuss more details of the results and their outcome risks and preventive strategies.

• More description is required to explain the association between key points and the conclusion.

• In this article not a single graphical representation has been included, add approximately 3 to 4 figures or graphs to strengthen your research manuscript.

• There are a few formatting mistakes, for this deeply review the article.

• Many references are missing or inconsistent in format.

• There are some grammatical mistakes in the manuscript, such as verbs and prepositions. The manuscript needs extensive review by an author.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Jun 24;17(6):e0270293. doi: 10.1371/journal.pone.0270293.r002

Author response to Decision Letter 0


24 Apr 2022

PONE-D-22-06018

Prevalence of depression and associated factors among adult cancer patients receiving chemotherapy during the era of COVID-19 in Ethiopia. A Hospital based cross sectional study

PLOSONE

Dear Dr. Belete,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Response: Dear editor, thank you very much for allowing us to revise our manuscript. We have tried to respond to each concern as much as possible. We have submitted a revised version of the manuscript.

I have received the reports from our advisors on your manuscript which you submitted to PLOS ONE.

Based on the comments received, I feel that your manuscript could be reconsidered for publication should you be prepared to incorporate major revisions. When preparing your revised manuscript, you are asked to carefully consider the reviewer comments below and submit a list of responses to the comments.

Author response: Dear editor, thank you for considering our manuscript publication. We have addressed the points raised by the reviewer and editors.

Editor Comments: The paper should be checked by a professional speaker of English before complete acceptance.

Author response: Dear editor, thank you very much. We have tried to edit the manuscript and also we used the online Grammarlly using the following links: https://www.grammarly.com/

Please submit your revised manuscript by May 19 2022 11:59 PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Author response: Dear editor, thank you. We have submitted per the due date.

Please include the following items when submitting your revised manuscript:

• A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

• A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

• An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Author response: Dear editor, thank you. We have included ‘Response to Reviewers', 'Revised Manuscript with Track Changes’, and ‘Manuscript’ separately.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

Author response: Dear editor, thanks for allowing us to update the financial disclosure. We have added it to the cover letter. Thanks for the suggestion for guidelines for figures.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial email&utm_source=authorletters&utm_campaign=protocols.

Author response: Dear editor, thank you for recommending depositing the laboratory protocols in protocols.io. But it is not applicable

We look forward to receiving your revised manuscript.

Kind regards,

Muhammad Sajid Hamid Akash

Academic Editor PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Author response: Dear Editor, we saw the link you invited me and I made corrections to the manuscript style to meet the requirement of PLOS ONE.

2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services. If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Author response: Dear editor, thank you for your suggestion.

Upon resubmission, please provide the following:

The name of the colleague or the details of the professional service that edited your manuscript

Author response: Dear Editor, we edit the manuscript by using an online grammar checker.

A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

Author response: Dear Editor, we have included manuscripts that contain track changes and uploaded them as manuscript track changes.

A clean copy of the edited manuscript (uploaded as the new *manuscript* file)”

Author response: Dear Editor, thank you. We have included a clean copy of the edited manuscript and uploaded them as a manuscript file.

3. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

Author response: Dear Editor, 1) consent was informed 2) the consent obtained was verbal informed consent. Detail of the study’s objective, method of data collection, and ethical concern were explained to potential participants, and they were requested to participate in the study voluntarily. For volunteer participants, data collectors tick the right sign in front of I agree, then continue interviewing the participant. There were no minors in this study, all were adults who can themselves give consent after understanding what was explained about the study. The study participants gave verbal consent to use their medical cards.

4. Thank you for stating the following financial disclosure:

"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

Author response: Dear Editor, sorry for making confused. It is a technical error this work had not received any form of support. All cost is covered by author.

State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

Author response: Dear Editor, again sorry. This study did not receive any form of support. Therefore, there is no funder.

b) If any authors received a salary from any of your funders, please state which authors and which funders.

Author response: Dear Editor, since no funder was participated so no author is received salary from funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Author response: Dear Editor, the authors received no specific funding for this work.

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Author response: Dear Editor, thank you very much. The amended statement is within the cover letter.

5. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

[Note: HTML markup is below. Please do not edit.]

Author response: Dear Editor, thank you for your recommendation. Already I have an ORCID id

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Author response: Dear reviewer, we have tried to modify it. See the revised track changes.

________________________________________

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Author response: Dear reviewer, thank you very much.

________________________________________

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Author response: Dear reviewer, thank you

________________________________________

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Author response: Dear reviewer, thank you very much

________________________________________

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Response: Dear editor, thank you very much. We have tried to answer the reviewer’s feedback and question as much as we can.

Reviewer #1: The author presented an original article on ‘Prevalence of depression and associated factors among adult cancer patients receiving chemotherapy during the era of COVID-19 in Ethiopia. A Hospital based cross sectional study’. The manuscript needs to be improved regarding the following aspects.

• Cancer chemotherapy should be described in detail to strengthen your research study moreover, overall associated factors for cancer risk should also be included in the introduction part, Biomed Pharmacother. 2021; 143: 112119. https://doi.org/10.1016/j.biopha.2021.112119

Author response: Dear reviewer, thank you for your recommendation. As per your recommendation, we have made an amendment to the revised manuscript.

• In the discussion section, discuss more details of the results and their outcome risks and preventive strategies.

Author response: Dear reviewer, thank you very much. We have tried to address all the points you raised in the revised manuscript.

• More description is required to explain the association between key points and the conclusion.

Author response: Dear reviewer, we have tried to add more description in the discussion part that links to a conclusion.

• In this article not a single graphical representation has been included, add approximately 3 to 4 figures or graphs to strengthen your research manuscript.

Author response: Dear reviewer, thank you very much for your effort to see each part of our work. According to your suggestion, we add 3 figures to the revised manuscript.

• There are a few formatting mistakes, for this deeply review the article.

Author response: Dear reviewer, we review deeply and modification was done in the revised manuscript.

• Many references are missing or inconsistent in format.

Author response: Dear reviewer, I made corrections as per your comment.

• There are some grammatical mistakes in the manuscript, such as verbs and prepositions. The manuscript needs extensive review by an author.

Author response: Dear reviewer, as per your comment I revise the manuscript for grammatical and spelling errors. The corrections are highlighted in the document entitled “revised manuscript with track changes”.

________________________________________

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Author response: Dear editor, thank you for your suggestion. We used the link that you invite me.

Attachment

Submitted filename: Response to reveiwer.docx

Decision Letter 1

Muhammad Sajid Hamid Akash

2 Jun 2022

PONE-D-22-06018R1Prevalence of depression and associated factors among adult cancer patients receiving chemotherapy during the era of COVID-19 in Ethiopia. Hospital-based cross-sectional studyPLOS ONE

Dear Dr. Belete,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

I have received the reports from our advisors on your manuscript which you submitted to PLOS ONE.

Based on the comments received, I feel that your manuscript could be reconsidered for publication should you be prepared to incorporate major revisions.

When preparing your revised manuscript, you are asked to carefully consider the reviewer comments below and submit a list of responses to the comments.

Editor Comments: There is a huge list of grammatical mistakes and syntax errors. The paper should be checked by a professional speaker of English before complete acceptance.

Please submit your revised manuscript by Jul 17 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Muhammad Sajid Hamid Akash

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The author presented an original article on “Prevalence of depression and associated factors among adult cancer patients receiving chemotherapy during the era of COVID-19 in Ethiopia. Hospital-based cross-sectional study”. The manuscript needs to be improved regarding the following aspects.

• The literature part is not up-to-date as I recommended you make changes in your manuscript that will strengthen your work. Again, I asked you to update the literature section by briefly explaining the cancer-associated risk factors and some of its novel therapeutic interventions. Biomed Pharmacother. 2021; 143: 112119. https://doi.org/10.1016/j.biopha.2021.112119. Biomed Pharmacother. 2018; 107: 1326-41. https://doi.org/10.1016/j.biopha.2018.08.116.

• The figures you have added are quite simple, more work is needed on graphics. Kindly revise them (figure1 and figure 2) with more creativity and diversity.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Jun 24;17(6):e0270293. doi: 10.1371/journal.pone.0270293.r004

Author response to Decision Letter 1


5 Jun 2022

PONE-D-22-06018R1

Prevalence of depression and associated factors among adult cancer patients receiving chemotherapy during the era of COVID-19 in Ethiopia. Hospital-based cross-sectional study

PLOS ONE

Dear Dr. Belete

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Response: Thank you very much for allowing us to revise our manuscript again. We have tried to response each concerns as much as possible. We have submitted a revised version of the manuscript.

I have received the reports from our advisors on your manuscript which you submitted to PLOS ONE.

Based on the comments received, I feel that your manuscript could be reconsidered for publication should you be prepared to incorporate major revisions.

When preparing your revised manuscript, you are asked to carefully consider the reviewer comments below and submit a list of responses to the comments.

Response: Again thank you very much. We will provide a list of response.

Editor Comments: There is a huge list of grammatical mistakes and syntax errors. The paper should be checked by a professional speaker of English before complete acceptance.

Response: we have extensively edited the manuscript for language usage, spelling, and grammar before submitting the revised version. The formatting of the text and document (text sizes and grammatical errors) were also edited. We have edited using the free editing chance at Trinka. Using the following link: https://www.trinka.ai

Additionally, we have extensively edited the manuscript by a professional language editor, (English-language speaker thoroughly edited the manuscript for language usage, spelling, and grammar) before submitting the revised version. His name is Dr. Menakath Menon.

Please submit your revised manuscript by Jul 17 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Response: we will provide on due date.

Please include the following items when submitting your revised manuscript:

• A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

• A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

• An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Response: Thank you. We have included ‘Response to Reviewers', 'Revised Manuscript with Track Changes and Manuscript separately

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

Response: thank you for reminding us on financial disclosure. The updated financial disclosure is given in the cover letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Response: thank you for your suggestion, but we haven’t any form of laboratory protocols.

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Response: sorry for inadequately addressed your concern. However, in the current version, all of your concern is updated as per your comments.

________________________________________

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Response: in fact your concern is appreciated. We have made extensive modification in the revised manuscript.

________________________________________

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Response: Thank you.

________________________________________

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Response: Thank you

________________________________________

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Response: Thank you.

________________________________________

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Response: thanks .We tried to address each and every question/concern step by step

Reviewer #1: The author presented an original article on “Prevalence of depression and associated factors among adult cancer patients receiving chemotherapy during the era of COVID-19 in Ethiopia. Hospital-based cross-sectional study”. The manuscript needs to be improved regarding the following aspects.

• The literature part is not up-to-date as I recommended you make changes in your manuscript that will strengthen your work. Again, I asked you to update the literature section by briefly explaining the cancer-associated risk factors and some of its novel therapeutic interventions. Biomed Pharmacother. 2021; 143: 112119. https://doi.org/10.1016/j.biopha.2021.112119. Biomed Pharmacother. 2018; 107: 1326-41. https://doi.org/10.1016/j.biopha.2018.08.116.

Response: Thank you for providing the most updated article. As per your suggestion we made modification in the revised manuscript.

• The figures you have added are quite simple, more work is needed on graphics. Kindly revise them (figure1 and figure 2) with more creativity and diversity.

Response: we tried to make more attractive.

________________________________________

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

________________________________________

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Response: thank you

Attachment

Submitted filename: authore response 2.docx

Decision Letter 2

Muhammad Sajid Hamid Akash

8 Jun 2022

Prevalence of depression and associated factors among adult cancer patients receiving chemotherapy during the era of COVID-19 in Ethiopia. Hospital-based cross-sectional study

PONE-D-22-06018R2

Dear Dr. Belete,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Muhammad Sajid Hamid Akash

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Muhammad Sajid Hamid Akash

17 Jun 2022

PONE-D-22-06018R2

Prevalence of depression and associated factors among adult cancer patients receiving chemotherapy during the era of COVID-19 in Ethiopia. Hospital-based cross-sectional study

Dear Dr. Belete:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Muhammad Sajid Hamid Akash

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Text. Sociodemographic questions.

    (DOCX)

    S2 Text. Clinical and behavioral characteristics of questions.

    (DOCX)

    S1 Table. Psychosocial questions.

    (DOCX)

    S2 Table. Socila support questions.

    (DOCX)

    S3 Table. Tools used to assess depression.

    (DOCX)

    S1 File. Data collection tool.

    (DOCX)

    Attachment

    Submitted filename: Response to reveiwer.docx

    Attachment

    Submitted filename: authore response 2.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES